News & Updates

Show Multimedia Only

Transcatheter ViV may be a safe short-term option to repeat MVR

18 Apr 2026 by

The transcatheter valve-in-valve (ViV) procedure appears to be a safe option for select patients requiring repeat surgery after failed mitral bioprostheses, according to findings from the randomized controlled SURViV trial presented at ACC.26. However, it is still early days for the ViV approach.

Transcatheter ViV may be a safe short-term option to repeat MVR

18 Apr 2026

Roflumilast cream effective in Chinese patients with plaque psoriasis

18 Apr 2026 by

Once-daily application of roflumilast cream 0.3% is associated with a significantly higher rate of treatment success on the Investigator's Global Assessment (IGA) scale in Chinese patients with plaque psoriasis compared with a vehicle cream, according to the phase III DERMIS-1 and -2 studies presented at AAD 2026.

Roflumilast cream effective in Chinese patients with plaque psoriasis

18 Apr 2026

IL-23 inhibitors work best at preventing PsA development in psoriasis

17 Apr 2026 by

Patients with psoriasis appear to have the lowest risk of developing psoriatic arthritis (PsA) when they are treated with IL-23 inhibitors than with other immunomodulatory agents, according to a real-world study.

IL-23 inhibitors work best at preventing PsA development in psoriasis

17 Apr 2026

Head and neck tumours linked to increased mortality in CMM patients

17 Apr 2026

Patients with cutaneous malignant melanoma (CMM) whose tumour is located in the head and neck (HN) are at greater risk of all-cause and cancer-specific mortality than those with tumours found in the trunk, reveals a study.

Head and neck tumours linked to increased mortality in CMM patients

17 Apr 2026

Methotrexate may lower CV risk in psoriasis patients

17 Apr 2026 by

Patients with psoriasis who are treated with methotrexate (MTX) show a reduced incidence of metabolic syndrome and better cardiometabolic profiles, according to a study presented at AAD 2026.

Methotrexate may lower CV risk in psoriasis patients

17 Apr 2026

Pegfilgrastim administered 72 h postchemo lessens bone pain

17 Apr 2026

Administrating pegfilgrastim 72 h after chemotherapy, compared with 24- and 48-h administration, results in reduced pegfilgrastim-induced bone pain (PIBP) and does not appear to increase the rates of neutropenia or febrile neutropenia (FN), reports a study.

Pegfilgrastim administered 72 h postchemo lessens bone pain

17 Apr 2026

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable

17 Apr 2026 by

Post-exposure prophylaxis-in-pocket (PIP) appears as effective as pre-exposure prophylaxis (PrEP) in improving quality of life (QoL) of individuals at low risk for HIV but may be a less costly option, according to a matched-control study presented at CROI 2026.

Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable

17 Apr 2026

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026 by

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

16 Apr 2026 by

Stopping beta-blockers after a year of regular use does not appear to increase the risk of adverse clinical outcomes in myocardial infarction (MI) survivors without evidence of left ventricular systolic dysfunction or heart failure (HF), as shown in the SMART-DECISION trial.

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

16 Apr 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Transcatheter ViV may be a safe short-term option to repeat MVR

Transcatheter ViV may be a safe short-term option to repeat MVR

Roflumilast cream effective in Chinese patients with plaque psoriasis

Roflumilast cream effective in Chinese patients with plaque psoriasis

IL-23 inhibitors work best at preventing PsA development in psoriasis

IL-23 inhibitors work best at preventing PsA development in psoriasis

Head and neck tumours linked to increased mortality in CMM patients

Head and neck tumours linked to increased mortality in CMM patients

Methotrexate may lower CV risk in psoriasis patients

Methotrexate may lower CV risk in psoriasis patients

Pegfilgrastim administered 72 h postchemo lessens bone pain

Pegfilgrastim administered 72 h postchemo lessens bone pain

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable

Post-exposure PIP comparable to PrEP for low-risk HIV, but more affordable

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year